Journal article icon

Journal article

Conservative management versus invasive management of significant traumatic pneumothoraces in the emergency department (the CoMiTED trial): a study protocol for a randomised non-inferiority trial

Abstract:
Introduction: Traumatic pneumothoraces are present in one of five victims of severe trauma. Current guidelines advise chest drain insertion for most traumatic pneumothoraces, although very small pneumothoraces can be managed with observation at the treating clinician’s discretion. There remains a large proportion of patients in whom there is clinical uncertainty as to whether an immediate chest drain is required, with no robust evidence to inform practice. Chest drains carry a high risk of complications such as bleeding and infection. The default to invasive treatment may be causing potentially avoidable pain, distress and complications. We are evaluating the clinical and cost-effectiveness of an initial conservative approach to the management of patients with traumatic pneumothoraces. Methods and analysis: The CoMiTED (Conservative Management in Traumatic Pneumothoraces in the Emergency Department) trial is a multicentre, pragmatic parallel group, individually randomised controlled non-inferiority trial to establish whether initial conservative management of significant traumatic pneumothoraces is non-inferior to invasive management in terms of subsequent emergency pleural interventions, complications, pain, breathlessness and quality of life. We aim to recruit 750 patients from at least 40 UK National Health Service hospitals. Patients allocated to the control (invasive management) group will have a chest drain inserted in the emergency department. For those in the intervention (initial conservative management) group, the treating clinician will be advised to manage the participant without chest drain insertion and undertake observation. The primary outcome is a binary measure of the need for one or more subsequent emergency pleural interventions within 30 days of randomisation. Secondary outcomes include complications, cost-effectiveness, patient-reported quality of life and patient and clinician views of the two treatment options; participants are followed up for 6 months. Ethics and dissemination: This trial received approval from the Wales Research Ethics Committee 4 (reference: 22/WA/0118) and the Health Research Authority. Results will be submitted for publication in a peer-reviewed journal. Trial registration number: ISRCTN35574247
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1136/bmjopen-2024-087464

Authors


More by this author
Role:
Author
ORCID:
0009-0002-9267-4848
More by this author
Role:
Author
ORCID:
0000-0001-6131-0916
More by this author
Role:
Author
ORCID:
0000-0001-7626-7519
More by this author
Role:
Author
ORCID:
0000-0002-3889-6098


Publisher:
BMJ Publishing Group
Journal:
BMJ Open More from this journal
Volume:
14
Issue:
6
Pages:
e087464-e087464
Publication date:
2024-06-01
DOI:
EISSN:
2044-6055
ISSN:
2044-6055


Language:
English
Keywords:
Pubs id:
2283013
Local pid:
pubs:2283013
Source identifiers:
W4399785247
Deposit date:
2025-08-21
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP